Successfully Outsourcing Formulation DevelopmentConsiderations for Emerging Biopharmaceutical Companies

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-08-01-2001
Volume 2001 Supplement
Issue 2

Successfully taking a new chemical entity from proof-of-concept to commercialization requires the biopharmaceutical company to carefully evaluate a contract services provider's formulation department and ability to become a fully integrated supplier.

External Link - article-5236.pdf

Articles in this issue
Creating a Successful Partnership with a Contract Manufacturer
Outsourcing Outlook
Creative Solutions in Client-CRO Relationships
Third-Party Technology Transfer
The Squeeze in Contract Manufacturing
Preparing Requests for Quotations for Commercial Pharmaceutical Manufacturing
Successfully Outsourcing Formulation DevelopmentConsiderations for Emerging Biopharmaceutical Companies
Stakes Rise for Blown Batches
Partnerships in Drug Discovery
Recent Videos
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Drug Digest: Strategic Partnerships
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content
Darmstadt, Germany - November 10, 2021: A building at the headquarters of science and technology company Merck KGaA. | Image Credit: © Anne Czichos - stock.adobe.com

MilliporeSigma and Simtra Launch Five-Year Agreement for Drug Substance, Drug Manufacturing Services

Patrick Lavery
June 11th 2025
Article

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Felicity Thomas
July 11th 2023
Podcast

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

3d rendering of Human cell or Embryonic stem cell microscope background. | Image Credit: © Anusorn - stock.adobe.com

Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck

John Tomtishen
May 28th 2025
Article

Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
May 2nd 2023
Podcast

In this episode, Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Feb 2, 2020 South San Francisco / CA / USA - Genentech headquarters in Silicon Valley; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009 | Image Credit: © Sundry Photography - stock.adobe.com

Genentech and Roche Expand US Footprint with New North Carolina Manufacturing Facility

Patrick Lavery
May 13th 2025
Article

The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Piramal Pharma to Invest $90 Million at Kentucky & Michigan Sites

Patrick Lavery
May 12th 2025
Article

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new tariff policies.